Curis, Inc.
Clinical trials sponsored by Curis, Inc., explained in plain language.
Develops targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug duo aims to deepen leukemia remission
Disease control Recruiting nowThis study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can improve outcomes for people with chronic lymphocytic leukemia (CLL) and other B-cell cancers. About 108 adults with CLL who have already received some treatment will take both drugs. The…
Phase 2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …
Phase 1/2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC